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Mammalian target of rapamycin complex 2
(mTORC2) phosphorylates and activates AGC kinase
family members, including Akt, SGK1, and PKC, in
response to insulin/IGF1. The liver is a key organ in
insulin-mediated regulation of metabolism. To
assess the role of hepatic mTORC2, we generated
liver-specific rictor knockout (LiRiKO) mice. Fed
LiRiKO mice displayed loss of Akt Ser473 phosphor-
ylation and reduced glucokinase and SREBP1c
activity in the liver, leading to constitutive gluconeo-
genesis, and impaired glycolysis and lipogenesis,
suggesting that the mTORC2-deficient liver is unable
to sense satiety. These liver-specific defects resulted
in systemic hyperglycemia, hyperinsulinemia, and
hypolipidemia. Expression of constitutively active
Akt2 in mTORC2-deficient hepatocytes restored
both glucose flux and lipogenesis, whereas glucoki-
nase overexpression rescued glucose flux but not
lipogenesis. Thus, mTORC2 regulates hepatic
glucose and lipid metabolism via insulin-induced
Akt signaling to control whole-body metabolic
homeostasis. These findings have implications for
emerging drug therapies that target mTORC2.
INTRODUCTION
Target of rapamycin (TOR) is a highly conserved protein kinase
that controls cell growth and metabolism in response to nutri-
ents, growth factors, and energy status. TOR exists in two
structurally and functionally distinct complexes termed TOR
complex 1 (TORC1) and TORC2 (Loewith et al., 2002). Mamma-
lian TORC1 (mTORC1) contains mTOR, raptor, and mLST8 and
phosphorylates a variety of substrates to control protein
synthesis, ribosome biogenesis, autophagy, and other growth-
related processes (Laplante and Sabatini, 2009; Polak and
Hall, 2009; Russell et al., 2011; Wullschleger et al., 2006). TheCtwo best-characterized mTORC1 substrates are ribosomal
protein S6 kinase (S6K) and eukaryotic initiation factor 4E-
binding protein (4E-BP), both of which control protein synthesis.
mTORC2 comprises mTOR, rictor, mSin1, mLST8, and PRR5
(also known as protor) and phosphorylates members of the
AGC kinase family, including Akt (also known as PKB), SGK1,
and PKC, via which mTORC2 controls cell survival, actin cyto-
skeleton organization, and other processes (Cybulski and Hall,
2009; Garcı´a-Martı´nez and Alessi, 2008; Ikenoue et al., 2008;
Jacinto et al., 2006; Jacinto et al., 2004; Sarbassov et al.,
2004; Yang et al., 2006). By regulating a wide range of anabolic
and catabolic processes, themTOR complexes play a key role in
growth, development, metabolism, and aging and are implicated
in a variety of pathological states including cancer, obesity, and
diabetes (Dazert and Hall, 2011).
Many studieswith geneticallymodified animals indicatemTOR
signaling plays a role in whole-animal metabolism and in the
development of disease. Full-body knockout of any component
of mTORC1 or mTORC2 causes embryonic lethality (Gangloff
et al., 2004; Guertin et al., 2006; Jacinto et al., 2006; Murakami
et al., 2004; Shiota et al., 2006; Yang et al., 2006). More recent
studies have focused onmTOR function specifically in metabolic
tissues, in large part due to these tissues being particularly
sensitive to the three inputs that control mTOR (nutrients, insulin,
and energy status). Conditional knockout of raptor (mTORC1) in
skeletal muscle results inmuscle dystrophy, glucose intolerance,
and short lifespan, whereas knockout of rictor (mTORC2) in skel-
etal muscle confers little to no phenotype (Bentzinger et al., 2008;
Kumar et al., 2008). Adipose-specific raptor knockout mice
display increased energy expenditure and resistance to diet-
induced obesity (Polak et al., 2008). Adipose-specific rictor
knockout mice are characterized by increased glucose metabo-
lism and somatic growth due to high circulating levels of insulin
and IGF1 (Cybulski et al., 2009; Kumar et al., 2010). In podocytes,
mTORC1 plays a role in the development of diabetic nephrop-
athy, whereas mTORC2 appears to have a minor role (Go¨del
et al., 2011; Inoki et al., 2011). Recent findings suggest that
hepatic mTORC1 controls ketogenesis and possibly lipidmetab-
olism (Kenerson et al., 2011; Sengupta et al., 2010; Yecies et al.,
2011). Together, the above studies suggest that the two mTOR
complexes contribute to whole-body metabolic homeostasisell Metabolism 15, 725–738, May 2, 2012 ª2012 Elsevier Inc. 725
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of mTORC2 in the liver remains to be determined.
The liver plays a central role in whole-body glucose and lipid
homeostasis (Postic et al., 2004). In the fasted state, the liver
maintains blood glucose levels by producing glucose via
glycogen breakdown and via gluconeogenesis. In the postpran-
dial state (i.e., satiety—the increased availability of glucose and
insulin), the liver ceases to produce glucose and takes up ex-
cess circulating glucose to replenish glycogen and triglyceride
(TG) stores. Insulin is the major hormone controlling the fasted
to postprandial transition (Saltiel and Kahn, 2001). In type 2
diabetes, hepatic insulin resistance leads to altered glucose
metabolism and thereby hyperglycemia. Insulin signals through
the PI3K-Akt pathway to inhibit gluconeogenesis and activate
glycolysis and lipogenesis. Akt inhibits expression of gluconeo-
genic genes, by inhibiting FoxO (Puigserver et al., 2003), and
induces glycolytic and lipogenic genes, by activating sterol regu-
latory element-binding protein 1c (SREBP1c) and glucokinase
(GK). SREBP1c is a transcription factor that promotes expres-
sion of a number of lipogenic genes (Horton et al., 2002). GK,
the rate-limiting enzyme of glycolysis in the liver, stimulates
glycolysis and lipogenesis by enhancing glucose flux, including
production of acetyl-CoA for lipid synthesis (Foufelle and Ferre´,
2002). Furthermore, GK stimulates glycolysis and lipogenesis
at the transcriptional level via the carbohydrate responsive
element-binding protein (ChREBP) (Uyeda and Repa, 2006).
Thus, the combined action of insulin signaling and glucose flux
regulates glucose and lipid metabolism in the liver.
mTORC2 phosphorylates Ser473 in the so-called hydrophobic
motif of Akt and thereby activates Akt toward some but not all
substrates (Guertin et al., 2006; Jacinto et al., 2006; Sarbassov
et al., 2005; Shiota et al., 2006; Yang et al., 2006; Zinzalla
et al., 2011). To elucidate the role of mTORC2 in the liver in vivo,
we generated liver-specific rictor knockout mice and investi-
gated Akt signaling and glucose and lipid metabolism. We find
that the mTORC2-deficient liver is unable to sense the state of
satiety. Hepatic mTORC2 activates both Akt signaling and
glucose flux to control glucose and lipid metabolism in the liver
and thereby overall metabolic homeostasis.
RESULTS
mTORC2 Deficiency in the Liver Leads to
Hyperglycemia, Hyperinsulinemia, and Hypolipidemia
To investigate the role of mTORC2 in the liver, we generated
mice lacking rictor, an essential and specific component of
mTORC2, exclusively in the liver (see Experimental Procedures).
Liver-specific rictor knockout (rictorfl/fl Alb-CreTg/0) mice (LiRiKO
mice) were viable, born at the expected frequency for Mendelian
inheritance, and showed normal fertility. In all subsequent exper-
iments, littermates without the Cre transgene (rictorfl/fl) were
used as controls. In LiRiKO mice, rictor protein was absent
only in the liver (Figure S1A). To evaluate mTORC2 activity, we
investigated the phosphorylation status of mTORC2 substrates
in the liver of mice treated with insulin. mTORC2 phosphorylates
the hydrophobic (Ser473) and turn (Thr450) motifs in Akt (Facchi-
netti et al., 2008; Ikenoue et al., 2008; Jacinto et al., 2006; Sar-
bassov et al., 2005; Yang et al., 2006). Akt phosphorylation at
these two sites was significantly reduced in LiRiKO liver (Fig-726 Cell Metabolism 15, 725–738, May 2, 2012 ª2012 Elsevier Inc.ure 1A). Phosphorylation of Akt Thr308, a site in the catalytic
loop phosphorylated by PDK1, was normal. mTORC2 also
phosphorylates and thereby controls the stability and activity
of PKCa and SGK1, respectively (Garcı´a-Martı´nez and Alessi,
2008; Ikenoue et al., 2008). As expected, PKCa protein levels
and phosphorylation of the SGK1 substrate NDRG1 were
decreased in LiRiKO liver (Figure 1A). These observations
confirm that both rictor protein and mTORC2 activity are absent
in the liver of LiRiKO mice.
We next examined systemic parameters of LiRiKO mice fed
a normal (chow) or high-fat diet (HFD). On a chow diet, LiRiKO
mice showed normal growth rates (Figure 1B) and normal body
composition (Figure S1B). When fed a HFD for 10 weeks, LiRiKO
mice were slightly lighter than controls, but this difference was
not statistically significant (Figure S1C). After 20 weeks on
a HFD, fat mass was significantly reduced (5%) in LiRiKO mice
(Figure S1D). This was likely due to increased lipolysis and
mitochondrial oxidation in adipose tissue of LiRiKO mice, as
suggested by an increased level of plasma glycerol (Figure S1E)
and increased expression of genes involved in lipolysis andmito-
chondrial oxidation in adipose tissue (Figure S1F). Analysis of
plasma parameters revealed that plasma TG and cholesterol
(total and HDL cholesterol) levels were significantly lower (Fig-
ure 1C), while plasma glucose (Figure 1D) and insulin (Figure 1E)
levels were significantly higher, in both fasted and chow-fed
LiRiKO mice. The same differences in blood parameters were
observed with mice on a HFD (Figures S1G–S1I). The levels of
ALT and AST were similar for the two genotypes (Figures S1J
and S1K). Thus, deletion of mTORC2 in the liver leads to hyper-
glycemia, hyperinsulinemia, and hypolipidemia, suggesting that
hepatic mTORC2 mediates metabolic homeostasis.
The liver of LiRiKO mice displayed normal gross morphology
(data not shown), and normal cell size and histopathology (Fig-
ure 1F). However, the weight of the liver of LiRiKO mice was
20% less compared to controls, for mice fed ad libitum either
a chow or a HFD (Figures 1G and S1L). This difference was not
observed in fasted mice (Figure S1M). Further analysis revealed
that glycogen and TG levels in the liver of fed LiRiKO mice were
significantly lower compared to controls (Figures 1F, 1H, 1I, and
S1N). Thus, loss of hepaticmTORC2 results in a smaller liver with
reduced glycogen and TG content in fed mice.
Deletion of mTORC2 in the Liver Causes Glucose
Intolerance
LiRiKO mice developed mild hyperglycemia and hyperinsuline-
mia at a young age (6 weeks), indicating that impaired glucose
homeostasis is an early effect of mTORC2 loss in the liver
(Figures S2A and S2B). To evaluate further whole-body glucose
homeostasis, we performed a glucose tolerance test (GTT) and
an insulin tolerance test (ITT). In the GTT, LiRiKO mice exhibited
significantly higher blood glucose levels before and after glucose
administration (Figure 2A). Plasma insulin levels were also signif-
icantly higher in LiRiKO mice (Figure 2B). The glucose intoler-
ance became more pronounced in older (>8 months) LiRiKO
mice (Figure S2C). In the ITT, when the mice were fasted for
6 hr before the experiment, LiRiKO mice showed normal insulin
sensitivity (Figure 2C). In contrast, when the mice were fasted
overnight, LiRiKO mice showed slightly but significantly
decreased glucose clearance (Figure 2D). The fact that lower
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Figure 1. LiRiKO Mice Develop Hyperglycemia, Hyperinsulinemia, and Hypolipidemia
(A) Western blots showing loss of rictor expression and mTORC2 activity in the liver of LiRiKO mice. Fasted mice were injected with insulin as described in
Experimental Procedures.
(B) Body weight (BW) gain of mice on a chow diet (n = 12 for control, n = 19 for LiRiKO). BW was monitored every week from 6 weeks of age for 26 weeks.
(C) Plasma total cholesterol (CHOL), HDL cholesterol (HDLC), LDL cholesterol (LDLC), and TG levels of ad libitum fed mice (n = 6 per group).
(D and E) Blood glucose (D) and plasma insulin (E) levels of overnight fasted and ad libitum fed mice (n = 8 for control and n = 6 for LiRiKO).
(F) Representative images of H&E, PAS, and oil red O staining of liver sections from ad libitum fed mice. Original magnification, 340.
(G) Liver weight (normalized to BW) of 10- to 18-week-old mice fed ad libitum (n = 12–13 per group).
(H) Hepatic glycogen content of mice after 4 hr refeeding (n = 7 per group).
(I) Hepatic TG content ofmice after 4 hr refeeding (n = 7 per group). Black bars represent control mice andwhite bars represent LiRiKOmice. Values are expressed
as mean ± SEM. * indicates statistical significance from control mice (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 2. Deletion of mTORC2 in the Liver Causes Glucose Intolerance
(A andB) Glucose tolerance test (GTT) in overnight fasted 14-week-oldmice.Mice were injectedwith glucose (2 g/kg) and blood glucose (A) and plasma insulin (B)
levels were measured at the indicated times. Bar graphs to the right show the respective area under the curve (AUC) of glucose and insulin (n = 7–8 per group).
(C and D) Insulin tolerance test (ITT) in 6 hr fasted (C) and overnight fasted (D) 16-week-old mice. Mice were injected with insulin (0.5 or 0.25 IU/kg, ip), and blood
glucose levels were measured at the indicated times. Results are expressed as percentage of the initial blood glucose levels. Bar graphs to the right show the
respective inverse area under the curve (AUC) of glucose (n = 6–7 per group).
Values are expressed as mean ± SEM. * indicates statistical significance from control mice (*p < 0.05, **p < 0.01, ***p < 0.001).
(E) Insulin-stimulated phosphorylation of Akt in the liver, skeletal muscle, and epididymalWAT of control and LiRiKOmice. Fourteen-week-oldmice were injected
with insulin as described in Experimental Procedures.
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night fasting, when hepatic gluconeogenesis is more active,
suggests that LiRiKO mice have hepatic insulin resistance but
normal insulin sensitivity in other tissues. Consistent with this,
insulin-induced activation of Akt was normal in both skeletal
muscle and adipose tissue in LiRiKO mice (Figure 2E). However,
older LiRiKO mice (>8 months) showed impaired glucose clear-
ance even after 6 hr fasting (Figure S2E), suggesting that whole-
body insulin sensitivity decreased with age as a consequence of
chronic hyperinsulinemia. When fed a HFD, LiRiKO mice dis-
played glucose intolerance (Figure S2F) and moderate insulin
resistance (Figure S2G) already at 14 weeks of age. Thus, LiRiKO728 Cell Metabolism 15, 725–738, May 2, 2012 ª2012 Elsevier Inc.mice develop diabetes (glucose intolerance, hyperinsulinemia,
and insulin resistance), further suggesting that hepatic mTORC2
controls whole-body metabolic homeostasis.
HepaticmTORC2 Is Required for Insulin-Akt Signaling to
FoxO1 and GSK3a/b but Not to mTORC1
The above findings suggest that the primary defect of a hepatic
mTORC2 deficiency may be insulin resistance in the liver. To
investigate this further, we examined insulin signaling, in partic-
ular insulin-activated Akt signaling, in the liver. Previous studies
have shown that mTORC2 (i.e., Akt Ser473 phosphorylation)
appears to be necessary for Akt activity toward some but not
AB
Figure 3. Hepatic mTORC2 Is Required for Insulin-Akt Signaling to
FoxO1 and GSK3a/b but Not to mTORC1
(A) Western blots of signaling molecules involved in the Akt and mTORC1
pathway in primary hepatocytes stimulated with 50 nM insulin for 30 min.
(B) Western blots of signaling molecules involved in the Akt and mTORC1
pathway in the liver of fasted and refed mice. Fourteen- to sixteen-week-old
mice (n = 4–6 per condition) were either fasted or refed a chow diet for 2 hr.
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Hall, 2006; Sarbassov et al., 2005; Shiota et al., 2006; Yang et al.,
2006). We first analyzed the phosphorylation status of Akt and
several Akt downstream effectors in insulin-stimulated primary
hepatocytes. In control hepatocytes, insulin stimulated phos-
phorylation of Akt (Ser473 and Thr308), GSK3a/b (Ser21 and
Ser9), FoxO1 (Thr24), S6K (Thr389), and S6 (Ser235/236) (Fig-
ure 3A). In LiRiKO hepatocytes, insulin failed to stimulate Akt
Ser473 phosphorylation whereas Thr308 phosphorylation was
normal (Figure 3A), confirming our in vivo findings describedCabove. The Akt substrates GSK3a/b and FoxO1 were signifi-
cantly hypophosphorylated in insulin-treated LiRiKO hepato-
cytes (Figure 3A). Importantly, phosphorylation of the Akt down-
stream effectors S6K and S6 was normal, supporting the
previous finding that Ser473 phosphorylation is not necessary
for Akt to signal to mTORC1. Next, we examined Akt effectors
in the liver of fasted and refed mice. Refeeding stimulated phos-
phorylation in control and LiRiKO livers in the same manner as
observed in insulin-stimulated control and LiRiKO hepatocytes
(Figure 3B). The only noteworthy exception in results obtained
with hepatocytes versus livers is that Akt Thr308was hyperphos-
phorylated in the liver of fasted and refed LiRiKO mice (Fig-
ure 3B). This is consistent with the hyperinsulinemia and
increased tyrosine phosphorylation of the insulin receptor in
LiRiKO mice (Figure 3B). Thus, hepatic mTORC2 is required for
insulin-Akt signaling to FoxO1 and GSK3a/b, but not for
insulin-Akt signaling to mTORC1. Furthermore, these findings
confirm hepatic insulin resistance, albeit partial, in LiRiKO mice.
Loss of mTORC2 Results in Dysregulated Hepatic
Gluconeogenesis and Glycolysis
How might the observed defect in hepatic insulin signaling lead
to defects in metabolic homeostasis, e.g., hyperglycemia? As
shown above, FoxO1 is hypophosphorylated in the liver of
refed LiRiKO mice (Figure 3B). FoxO1 is a transcription factor
that functions with the transcriptional coactivator PGC1a to
induce gluconeogenic genes such as glucose-6-phosphatase
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) in
the fasted state. During the fasted to postprandial transition,
FoxO1 is phosphorylated by Akt, which results in nuclear exclu-
sion of FoxO1 and inihibition of gluconeogenesis (Matsumoto
et al., 2007; Puigserver et al., 2003). Consistent with hypophos-
phorylation of FoxO1 in the liver of LiRiKO mice, nuclear exclu-
sion of FoxO1 in response to feeding was severely impaired
(Figure 4A). Furthermore, visualization of FoxO1 by immunos-
taining revealed that FoxO1 is preferentially localized in the
nucleus in LiRiKO hepatocytes (Figures 4B and S3A). To further
investigate the regulation of gluconeogenesis, we examined
glucose production and gluconeogenic gene expression. LiRiKO
hepatocytes exhibited higher basal glucose production, which
was less inhibited by insulin, as compared to controls (Figure 4C).
Consistent with these observations, mRNA levels of PEPCK and
G6Pase in basal and insulin-treated conditions were significantly
higher in LiRiKO hepatocytes (Figure S3B). Higher mRNA levels
of gluconeogenesis-related geneswere also observed in the liver
of refed LiRiKO mice (Figure 4D). Finally, in a pyruvate challenge
test, LiRiKO mice showed mildly but significantly higher blood
glucose levels compared to controls, further suggesting
increased hepatic glucose production capacity (Figure S3C).
Thus, gluconeogenesis is constitutively active in the liver of LiR-
iKO mice, accounting for the observed high levels of blood
glucose in both fasted and fed LiRiKO mice.
To further investigate the cause of the hyperglycemia, we
examined hepatic glucose uptake and glycolysis. Glucose
uptake was significantly reduced in LiRiKO hepatocytes com-
pared to control hepatocytes (Figure 4E). Glucose uptake by
hepatocytes is determined by the rate of glycolysis which is
mainly dependent on GK activity (Ferre et al., 1996). GK, the
first enzyme in the glycolytic pathway, is induced by insulinell Metabolism 15, 725–738, May 2, 2012 ª2012 Elsevier Inc. 729
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Figure 4. Loss of mTORC2 Results in Active FoxO1 and Constitutively Elevated Hepatic Gluconeogenesis, Reduced Glucokinase Expres-
sion, and Glucose Flux
(A) FoxO1 protein levels in nuclear fractions from the liver of fasted and refed mice.
(B) Immunofluorescent staining of FoxO1 in primary hepatocytes isolated from control and LiRiKO mice.
(C) Glucose production from primary hepatocytes. Hepatocytes were incubated in glucose production media in the presence or absence of insulin, and glucose
release into the media was measured after 12 hr incubation. Results are representative of three independent experiments. Results are normalized to the level of
control without insulin.
(D) mRNA levels of G6Pase, PEPCK, and PGC-1a in the liver of control and LiRiKOmice after overnight fasting and after 4 hr of refeeding. Results are normalized
to the levels of fasted control mice.
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Hepatic mTORC2 Mediates Metabolic Homeostasisand converts glucose to glucose-6-phosphate (G6P). G6P is
metabolized through glycolysis, glycogen synthesis, and via
the pentose phosphate shunt. In the liver of LiRiKO mice, GK
was markedly decreased, as determined by the levels of GK
mRNA, protein, and activity (Figures 4F–4H). This correlated
with decreased ChREBP expression and nuclear translocation
(Figures 4F and S3D), and low expression of a ChREBP target
gene (L-pyruvate kinase) in LiRiKO liver (Figure 4F). Furthermore,
insulin-induced glycogen synthesis was also significantly
decreased in LiRiKO hepatocytes (Figure S3E). The reduced
glycogen synthesis in LiRiKO liver could be explained not
only by reduced glucose uptake, but also by lower glycogen
synthase (GS) activity, as indicated by higher GS phosphoryla-
tion (Figure S3F). This was consistent with the observed hypo-
phosphorylation of GSK3, a kinase responsible for inhibitory
phosphorylation of GS, in LiRiKO liver (Figure 3B). In contrast,
GLUT2 expression in the liver of LiRiKO mice was not changed
(Figures S3G and S3H). Taken together, these results indicate
that glucose uptake, glycolysis, and glycogen synthesis are
impaired in the liver of LiRiKO mice, possibly due to decreased
mTORC2-mediated insulin-induced GK expression. Thus,
constitutive gluconeogenesis and defective glycolysis (and
glycogen synthesis) together account for the observed hypergly-
cemia. Furthermore, the above findings suggest that defective
mTORC2-Akt signaling (hepatic insulin resistance) accounts for
the hyperglycemia in LiRiKO mice.
Hepatic mTORC2 Is Required for Insulin-Stimulated De
Novo Lipid Synthesis
The glycolytic defect described above and the decreased TG
levels in the liver of LiRiKO mice suggested that mTORC2 is
required for hepatic lipogenesis. Hepatic lipogenesis is induced
by insulin via stimulation of lipogenic gene expression. To
investigate lipogenesis, we examined both lipogenic gene
expression in the liver of refed mice and de novo lipid synthesis
in insulin-stimulated primary hepatocytes. mRNA levels of the
key lipid synthesis enzymes, including ATP citrate lyase
(ACL), acetyl-CoA carboxylase (ACC), fatty acid synthase
(FAS), stearoyl-CoA desaturase (SCD1), glycerol-3-phosphate
acyl transferase (GPAT), and diacylglycerol acyl transferase
(DGAT2), were all significantly decreased in the liver of refed
LiRiKO mice (Figure 5A). In addition, mRNA expression of
SREBP1c and PPARg, two transcription factors that activate
lipogenic genes, was significantly reduced in LiRiKO liver (Fig-
ure 5A). De novo lipid synthesis was also significantly decreased
in insulin-stimulated LiRiKO hepatocytes (Figure 5B). Thus,
impaired lipid synthesis in the liver of LiRiKOmice is due, at least
in part, to decreased expression of lipogenic genes. Conversely,
genes related to fatty acid oxidation, such as acyl-CoA oxidase
(ACO), carnitine palmitoyltransferase 1 (CPT1), and PPARa, were
increased in fasted LiRiKO mice (Figure S5A). This observation
together with a trend of increased plasma ketone bodies (b-hy-(E) 2-deoxyglucose uptake in primary hepatocytes. Results are representative of
(F) mRNA expression levels of GK, liver-type pyruvate kinase (PK) and ChREBP in
(G) Western blot analysis of GK expression in the liver of ad libitum fed mice.
(H) Enyzmatic activity of GK and hexokinase in the liver of ad libitum fed mice. Res
bars represent control, and white and light gray bars represent LiRiKO (n = 6–7 pe
significance from control, # indicates statistical significance from respective fast
Cdroxybutyrate) (Figure S5B) suggests higher fatty acid oxidation
in the liver of LiRiKO mice. Moreover, expression of genes en-
coding fatty acid uptake, including fatty acid-binding protein 1
(FABP1) and CD36, was significantly decreased in the liver of
HFD-fed LiRiKO mice, while expression of genes encoding
fatty acid export, including ApoB and MTP, was unaffected (Fig-
ure S5C). Taken together, these observations suggest that the
mTORC2-deficient liver displays reduced TG levels due to
reduced lipogenesis, increased fatty acid oxidation, and
reduced uptake.
Postprandial expression of lipogenic genes ismediatedmainly
by insulin-induced activation of SREBP1c (Shimomura et al.,
1999). SREBP1c is synthesized as an ER bound precursor.
Upon activation by insulin, SREBP1c moves to the Golgi where
it is proteolytically processed into a mature form. The cleaved
mature form of SREBP1c translocates into the nucleus, where it
upregulates target lipogenic genes (Horton et al., 2002). Insulin-
mediated activation of SREBP1c is Akt dependent (Yellaturu
et al., 2009a). Interestingly, recent cell culture-based studies
suggest that Akt stimulates lipogenesis via mTORC1-dependent
SREBP1 activation (Du¨vel et al., 2010; Li et al., 2010; Peterson
et al., 2011; Porstmann et al., 2008; Yecies et al., 2011), whereas
mainly in vivo studies suggest that Akt activates SREBP1c and
lipogenesis via an mTORC1-independent pathway (Wan et al.,
2011; Yecies et al., 2011). To investigate further the role of
mTORC2(-Akt) signaling in lipogenesis, we examined SREBP1c
activation in the liver of refed LiRiKOmice. In particular, we exam-
ined the levels of precursor and mature forms of SREBP1c. The
mature nuclear form of SREBP1c was significantly decreased
in the liver of refed LiRiKO mice, whereas the precursor form
was unchanged (Figure 5C), suggesting that the posttranslational
activation of SREBP1c is defective in LiRiKO liver. Expression of
the SREBP1c target genes ACC and FAS was reduced (Figures
5A and 5C). Thus, mTORC2 is required for SREBP1c activation
and lipogenesis in the liver.
Constitutively Active Akt2 Restores Glucose Flux and
Lipogenesis in mTORC2-Deficient Hepatocytes
The above findings suggest that loss of hepatic mTORC2 results
in defective Akt activation (Ser473 phosphorylation) which even-
tually results in impaired metabolic homeostasis. To investigate
further whether loss of mTORC2-mediated Akt Ser473 phos-
phorylation is responsible for the defects in glycolysis and lipo-
genesis observed in LiRiKO hepatocytes, we determined if
a constitutively active Akt is able to suppress these defects. By
adenoviral gene transfer, we introduced an Akt2 mutant in which
Ser474 (equivalent to Ser473 in Akt1) is mutated to phosphomi-
metic aspartic acid (Akt2-S474D). This Akt mutant does not
require mTORC2 for activation and is thus considered con-
stitutively active. LacZ and wild-type Akt2 (Akt2-WT) were
used as controls. Insulin-stimulated phosphorylation of Akt
substrates FoxO1 and GSK3b was significantly reduced inthree independent experiments.
the liver of 4 hr refed mice. Results are normalized to the levels of control mice.
ults are representative of three independent experiments. Black and dark gray
r group for mice). Values are expressed as mean ± SEM. * indicates statistical
ed or untreated control. (*, #p < 0.05, **, ##p < 0.01, ***, ###p < 0.001).
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Figure 5. Hepatic mTORC2 Is Required for Insulin-
Stimulated De Novo Lipid Synthesis
(A) mRNA levels of genes involved in de novo lipid
synthesis including ACL, ACC1, FAS, SCD1, GPAT,
DGAT1/2, SREBP1c, and PPARg, in the liver of mice after
4 hr refeeding. Results are normalized to the levels of
control mice. Black bars represent control mice and white
bars represent LiRiKO mice (n = 6–7 per group).
(B) De novo lipid synthesis in primary hepatocytes. Serum-
starved primary hepatocytes were stimulated with 50 nM
insulin for 12 hr. 14C-labeled acetate incorporation into
cellular lipids was determined as described in Experi-
mental Procedures. Results are representative of three
independent experiments. Black and dark gray bars
represent control hepatocytes, and white and light gray
bars represent LiRiKO hepatocytes.
(C) SREBP1c processing was analyzed by western blot
analysis on nuclear and cytosolic fractions from the liver of
mice after 4 hr refeeding. The precursor form of SREBP1c
(SREBP1c(p)) was detected in cytosolic fraction andwhole
cell lysates, and the mature form of SREBP1c
(SREBP1c(m)) was detected in nuclear fraction. HDAC1
and Erk were used as marker proteins of nuclear and
cytosolic fractions, respectively. Protein levels of
SREBP1c target genes (ACC and FAS) were also analyzed
using whole-cell lysates. Bar graph to the right represents
quantification of band intensities of SREBP1c normalized
to its respective internal control. Average value from fasted
controls was set to 1. Values are the mean ± SEM, * indi-
cates statistical significance from control, and # indicates
statistical significance from respective insulin-untreated
control (*, #p < 0.05, **, ##p < 0.01, ***, ###p < 0.001).
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Hepatic mTORC2 Mediates Metabolic HomeostasislacZ- or Akt2-WT-expressing LiRiKO hepatocytes compared to
control hepatocytes (Figure 6A). In contrast, mild overexpression
of Akt2-S474D increased insulin-stimulated phosphorylation of
FoxO1 and GSK3b in LiRiKO hepatocytes, as in control hepato-
cytes (Figure 6A). Importantly, restoration of Akt signaling in
LiRiKO hepatocytes suppressed the previously observed
defects in glucose uptake (Figure 6B) and de novo lipid synthesis
(Figure 6C). Furthermore, Akt2-S474D restored expression of
GK, SREBP1c, and FAS, in LiRiKO hepatocytes (Figure 6D).
Thus, mTORC2-mediated Akt phosphorylation is essential for
insulin-induced glycolysis and lipid synthesis in the liver.
Restoration of Glucose Flux Is Not Sufficient to Rescue
De Novo Lipid Synthesis in mTORC2-Deficient
Hepatocytes
mTORC2-mediated Akt phosphorylation enhances both insulin
signaling and glucose flux, which then contribute to activation
of lipogenesis (see Introduction and above). To investigate if
the defect in lipogensis observed in LiRiKO hepatocytes is due
to a defect in glucose flux, we restored glucose flux by overex-732 Cell Metabolism 15, 725–738, May 2, 2012 ª2012 Elsevier Inc.pressing GK (Figure 7A) and examined if this
was sufficient to suppress the lipogenesis
defect. Overexpressed GK enhanced glucose
uptake to a similar extent in LiRiKO and control
hepatocytes (Figure 7B). Consistent with
elevated glucose uptake, expression of genes
encoding ChREBP, pyruvate kinase, and lipo-
genic enzymes (FAS, ACC1/2) was significantlyincreased in GK-overexpressing LiRiKO and control hepato-
cytes (Figure 7C). However, the defect in de novo lipid synthesis
was not suppressed in LiRiKO hepatocytes (Figure 7D). Whereas
de novo lipid synthesis was significantly elevated upon GK over-
expression, the increase was similar to that observed in control
cells (about 2.6-fold), and LiRiKO hepatocytes still displayed
only 30% activity compared to control cells (Figure 7D). Thus,
glucose flux, although required, is not sufficient to induce lipo-
genesis. Overexpressed GK did not suppress the defect in Akt
Ser473 phosphorylation (Figure 7A) or rescue expression of
SREBP1c and its target gene SCD1 (Figure 7C), indicating that
activation of Akt and SREBP1c is essential for lipogenesis in
the liver. Taken together, the above findings suggest that
mTORC2 activates Akt, which stimulates glycolysis and lipogen-
esis via GK and SREBP1c (Figure 7E).
DISCUSSION
In this study, we demonstrate that deletion of mTORC2 in the
liver (LiRiKO mice) leads to enhanced gluconeogenesis and
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Figure 6. Expression of Constitutively
Active Akt2 Restores Glucose Uptake and
Lipogenesis in mTORC2-Deficient Hepato-
cytes
(A) Western blots of control (C) and LiRiKO (K)
hepatocytes infected with adenoviruses express-
ing lacZ, Akt2-WT, and Akt2-S474D. Infected cells
were serum starved and stimulated with 50 nM
insulin for 30 min.
(B) Glucose uptake by hepatocytes infected with
adenoviruses as in (A).
(C) De novo lipid synthesis in hepatocytes infected
with adenoviruses as in (A).
(D) mRNA expression levels of GK, SREBP1c, and
FAS in hepatocytes infected with adenoviruses as
in (A). Results are normalized to the levels of lacZ
expressing control hepatocytes.
Values are the mean ± SEM. * indicates statistical
significance from control in the same condition
and # indicates statistical significance from
respective lacZ expressing control (*, #p < 0.05, **,
##p < 0.01, ***, ###p < 0.001).
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Hepatic mTORC2 Mediates Metabolic Homeostasisdecreased glycolysis, glycogen synthesis, and lipogenesis in the
fed state, despite hyperglycemia and hyperinsulinemia. This
suggests that the mTORC2-deficient liver is unable to make
the fasted to postprandial transition. In other words, the
mTORC2-deficient liver cannot sense satiety. The constitutively
active gluconeogenesis was due to loss of both Akt Ser473
phosphorylation and FoxO1 inhibition, and decreased glycolysis
was due to reduced GK and glucose uptake. These two defects
in hepatic glucose metabolism in turn led to systemic hypergly-Cell Metabolism 15, 725cemia and hyperinsulinemia. The
decreased hepatic lipogenesis was due
to reduced SREBP1c activation and low
glucose flux. Finally, constitutively active
Akt restored both glucose uptake and
lipogenesis, whereas overexpression of
GK (enhanced glucose flux) failed to
restore lipogenesis. Our findings sug-
gest that hepatic mTORC2 controls Akt
Ser473 phosphorylation, and thereby
GK and SREBP1c, to coordinate glucose
and lipid metabolism (Figures 7E and S5).
Another important observation in this
study is that LiRiKO mice are phenotypi-
cally similar (glucose intolerance, hy-
perglycemia, hyperinsulinemia, hypolipi-
demia, and smaller liver size with
decreased glycogen content) to many
other genetically modified mice that
have more severe defects in the hepatic
insulin-PI3K-Akt signaling pathway. The
mice with more severely defective insulin
signaling include liver-specific insulin
receptor knockout mice (Biddinger et al.,
2008; Michael et al., 2000), single and
double hepatic IRS1/2 knockout mice
(Dong et al., 2006; Kubota et al., 2008),
and mice with deletion of regulatorysubunits of PI3K in the liver (Miyake et al., 2002; Taniguchi
et al., 2006). Since insulin signaling is completely ablated in these
mice, a broad spectrum of downstream targets is affected,
including both mTORC1 and mTORC2. In contrast, deletion of
mTORC2 results in loss of phosphorylation of the hydrophobic
motif, including Akt Ser473 phosphorylation, in a subset of
AGC kinase family members, without affecting mTORC1
signaling. The loss of Akt Ser473 phosphorylation accounts for
constitutively active FoxO1 and GSK3 and for the loss of–738, May 2, 2012 ª2012 Elsevier Inc. 733
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Figure 7. Restoration of Glucose Flux Is Not
Sufficient to Rescue De Novo Lipid Syn-
thesis in mTORC2-Deficient Hepatocytes
(A) Western blots of hepatocytes infected with
adenoviruses expressing lacZ or GK.
(B) Glucose uptake by hepatocytes infected with
indicated adenoviruses.
(C) mRNA expression levels of glycolytic and
lipogenic genes. Results are normalized to the
levels of lacZ-expressing control hepatocytes.
(D) De novo lipid synthesis in hepatocytes infected
with indicated adenoviruses. Black and dark gray
bars represent control hepatocytes, white and
light gray bars represent LiRiKO hepatocytes.
Values are expressed as mean ± SEM of three
independent experiments. * indicates statistical
significance from control in the same condition
and # indicates statistical significance from
respective lacZ-expressing control (*, #p < 0.05, **,
##p < 0.01, ***, ###p < 0.001).
(E) Model for the role of mTORC2 in the liver.
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Hepatic mTORC2 Mediates Metabolic HomeostasisSREBP1c and GK activities, and thereby appears to be largely
responsible for the phenotype of LiRiKOmice. Thus, our findings
reveal a particularly important role for mTORC2 and Akt Ser473
phosphorylation in the hepatic insulin pathway in controlling liver
and whole-body metabolism.
Akt is a major regulator of insulin-induced lipogenesis in the
liver. Hepatic overexpression of constitutively active Akt or dele-
tion of hepatic PTEN increases TG synthesis (Horie et al., 2004;
Ono et al., 2003; Stiles et al., 2004). Conversely, liver-specific
deletion of Akt2, the major Akt isoform in the liver, protects
against diet- or PTEN loss-induced hepatic steatosis (He et al.,734 Cell Metabolism 15, 725–738, May 2, 2012 ª2012 Elsevier Inc.2010; Leavens et al., 2009). Akt promotes
lipid synthesis primarily through the acti-
vation of SREBP1c, a master transcrip-
tion factor of lipogenic genes. How does
Akt activate SREBP1c? Several cell
culture-based studies have suggested
that Akt activates SREBP1c and lipogen-
esis via mTORC1 (Du¨vel et al., 2010; Li
et al., 2010; Porstmann et al., 2008; Ye-
cies et al., 2011). Furthermore, a recent
study showed that mTORC1 regulates
SREBP by controlling nuclear transloca-
tion of lipin1, an inhibitor of SREBP
activity (Peterson et al., 2011). However,
recent animal-based studies using liver-
specific TSC1 or Akt2 knockout mice
have shown that mTORC1 activation is
not sufficient to stimulate SREBP1c
without Akt signaling (Kenerson et al.,
2011; Wan et al., 2011; Yecies et al.,
2011). Yecies et al. presented evidence
that Akt activates SREBP1c via inhibition
of expression of Insig2, an anchor protein
that retains SREBP1c on the ER mem-
brane (Yellaturu et al., 2009b). Another
potential mechanism by which Akt acti-vates SREBP1c is via Akt-mediated phosphorylation and inhibi-
tion of GSK3. GSK3 phosphorylates mature SREBP1 and
thereby promotes its degradation by the ubiquitin-proteasome
pathway (Bengoechea-Alonso and Ericsson, 2009; Kim et al.,
2004; Sundqvist et al., 2005). Which of the above mechanism(s)
of Akt-mediated activation of SREBP1c is defective in LiRiKO
mice? Our finding that SREBP1c activation and lipogenenesis
are impaired in LiRiKO liver, where mTORC2 is defective but
mTORC1 is active, suggest that Akt signals to SREBP1c in the
liver at least in part independently of mTORC1. Also, we
observed no significant difference in Insig2a expression in the
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Hepatic mTORC2 Mediates Metabolic Homeostasisliver of refed LiRiKO mice compared to controls (data not
shown). However, we did observe a defect in Akt-mediated
GSK3 phosphorylation and decreased expression of mature
SREBP1c. Thus, constitutively active GSK3 and enhanced
degradation of mature SREBP1c may be the mechanism under-
lying the observed defect in SREBP1c activation in LiRiKO mice.
Though Akt-activated SREBP1c is considered a primarymedi-
ator of insulin-stimulated lipogenesis, GK-activated glucose flux
also mediates induction of lipogenesis in the liver (Dentin et al.,
2005). In liver-specific GK knockout mice, glycolytic and lipo-
genic genes are not maximally induced upon refeeding, even
though SREBP1c activation is normal (Dentin et al., 2004). More-
over, a high carbohydrate diet induces expression of glycolytic
and lipogenic genes even in SREBP1c-deficient mice (Liang
et al., 2002). GK-dependent and SREBP1c-independent induc-
tion of glycolytic (pyruvate kinase) and lipogenic (FAS, ACC)
genes appears to be mediated by the transcription factor
ChREBP (Uyeda and Repa, 2006). GK is necessary for both
expression and activation of ChREBP. Therefore, GK/glucose
flux and SREBP1c act synergistically in the stimulation of lipo-
genesis. In the liver of LiRiKO mice, lipogenesis was impaired
due to a decrease in both GK and SREBP1c activity. The
decrease in GK expression in the liver of LiRiKO mice is due to
a decrease in Akt signaling (the defect is suppressed by acti-
vated Akt). GK gene expression is regulated by a number of
Akt-dependent transcriptional factors, including FoxO1, HIF-
1a/HNF4/p300, SREBP1c, LXRa, and PPARg (Hirota et al.,
2008; Kim et al., 2009;Massa et al., 2011; Roth et al., 2004).
Indeed, phosphorylation of FoxO1 and expression of SREBP1c
and PPARg were decreased in the liver of LiRiKO mice. Further
studies are required to determine which mTORC2-regulated
transcription factor(s) is lacking and thus unable to activate GK
expression in LiRiKO mice.
We provide evidence that overexpression of GK in LiRiKO
hepatocytes restores expression of glycolytic and lipogenic
genes in the absence of Akt Ser473 phosphorylation and
SREBP1cactivation.However, the level of de novo lipid synthesis
induced by GK overexpression in LiRiKO hepatocytes was less
than that of control hepatocytes overexpressing GK, despite
a similar rate of glucose uptake, suggesting that glucose flux is
not sufficient to stimulate lipogenesis. Akt signaling and
SREBP1cactivationarealso required for inductionof lipogenesis.
Thus, mTORC2 is required for the coordinated regulation, by GK
and SREBP1c, of insulin-induced glycolysis and lipogenesis.
In summary, the present study demonstrates the functional
importance of hepatic mTORC2 in the regulation of glucose
and lipid homeostasis. Hepatic mTORC2 inhibition results in
decreased glucose metabolism caused by decreased Akt
activity (loss of Akt Ser473 phosphorylation) and subsequently
reduced SREBP1c and GK activities. These defects in turn
lead to hyperglycemia and hyperinsulinemia. These findings
should be taken into account when considering clinical use of
emerging mTOR inhibitors that target mTORC2 in addition to
mTORC1 (Benjamin et al., 2011). Although detailed safety pro-
files of mTOR kinase inhibitors remain to be seen, inhibition of
mTORC2may contribute to adversemetabolic effects (Markman
et al., 2010; Zhang et al., 2011). Our findings suggest that a defect
in hepatic mTORC2 signaling could contribute to metabolic
disorders.CEXPERIMENTAL PROCEDURES
A complete version of Experimental Procedures is shown in Supplemental
Information.
Animals
rictorfl/fl mice were generated as described previously (Cybulski et al., 2009).
Liver-specific rictor knockout mice were generated by crossing rictorfl/fl mice
with transgenic mice expressing Cre recombinase under the control of the
hepatocyte specific albumin promoter (C57BL/6-Tg(Alb-cre)21Mgn/J; Jack-
son Laboratory). The resultant rictorfl/+ Alb-CreTg/0 progeny were crossed
with rictorfl/fl mice to obtain tissue-specific knockout mice (rictorfl/fl
Alb-CreTg/0), termed liver-specific rictor knockout (LiRiKO) mice. Littermates
without the Cre gene were used as wild-type control mice (rictorfl/fl). All exper-
iments were conducted on male mice between 12 to 17 weeks of age, unless
otherwise indicated. All experiments were performed in accordance with
federal guidelines and were approved by the Kantonales Veterinaeramt of
Kanton Basel-Stadt.
Glucose, Insulin, and Pyruvate Tolerance Tests
For glucose tolerance tests (GTT), mice were fasted overnight (16 hr) then
administrated 2 g/kg of body weight of glucose by intraperitoneal (i.p.) injec-
tion. For insulin tolerance tests (ITT), mice were fasted for 6 hr or overnight
before i.p. administration of 0.5 or 0.25 unit/kg of body weight of insulin
(Actrapid). For pyruvate challenge test, mice were fasted overnight then
administrated 2 g/kg of body weight of sodium pyruvate by i.p. injection. Blood
glucose concentrations were measured before and after the injection at the
indicated time points.
Adenovirus Generation
We generated adenoviruses encoding wild-type Akt2 and a phosphomimetic
Akt2-S474D mutant using the ViraPower Adenoviral Gateway Expression
System (Invitrogen). In brief, wild-type human Akt2 and a phosphomimetic
Akt2-S474D mutant, in which Ser at residue 474 is substituted by Asp, were
subcloned by PCR from pFastBac-PKBb and pFastBac- PKBb-S474D clones
(clones were kind gifts of Brian A. Hemmings, FMI, Switzerland) and cloned
into pDONR221 vectors. Entry clones and the pAd/CMV-DEST vector
were recombined to generate expression clones (pAd/CMV-Akt2-WT and
pAd/CMV-Akt-S474D). Each expression clone was transfected into
HEK293A cells to produce adenoviruses. After several amplifications by infect-
ing HEK293A cells, we determined the titer of each adenovirus. AxCA-GK and
AxCA-lacZ adenoviruses were a kind gift of Wataru Ogawa (Kobe University,
Japan).
Primary Hepatocyte Isolation and Cultures
Hepatocytes were isolated from 8- to 12-week-old male mice using the stan-
dard two-step collagenase perfusion protocol. Adenoviral infection experi-
ments were performed 3 hr after plating at an moi of 1 for Akt2 restoration
and moi of 5 for GK restoration. Six hours after infection, cells were washed
with PBS and incubated overnight with DMEM (5 mM glucose) containing
100 nM dexamethasone and 1 nM insulin. Experiments were performed the
next day. For insulin stimulation, hepatocytes were cultured in high glucose
DMEM (25 mM glucose) with 10 or 50 nM insulin for the indicated times.
Western Blotting
Whole-protein extraction from tissuewas performed as described (Polak et al.,
2008). Nuclear and cytosolic fractions were prepared using the NE-PER
nuclear protein extraction kit (Pierce). Lysates from primary hepatocytes
were prepared using lysis buffer containing 50 mM Tris-HCl (pH 8.0),
150 mM NaCl, 0.5 mM EDTA, 1% Triton, protease inhibitor, and phosphatase
inhibitor. Forty micrograms of protein were loaded for SDS-PAGE and
analyzed with the indicated antibodies. Immunoblots were performed using
the antibodies against the following proteins: rictor, Akt, Akt (pThr308), Akt
(pSer473), GSK3a/b, GSK3a/b (pSer9/21), FoxO1, FoxO1/3a (pThr24/32),
IRb/IGFRb, IRb/IGFRb (pTyr1146/1131), S6K1, S6K1 (pThr389), S6, S6
(pSer235/236), 4EBP, 4EBP (pThr37/46), ACC, FAS, Erk, and HDAC (all from
Cell Signaling), glucokinase and SREBP1c (Santa Cruz), ChREBP (Novusell Metabolism 15, 725–738, May 2, 2012 ª2012 Elsevier Inc. 735
Cell Metabolism
Hepatic mTORC2 Mediates Metabolic HomeostasisBiologicals), Glut2 (a kind gift from Bernard Thorens, University of Lausanne,
Switzerland), and actin (Chemicon).
RNA Isolation and Quantitative PCR
RNA isolation and cDNA synthesis were performed as described (Polak et al.,
2008). qPCR was performed using the power SYBR green mix (Applied
Biosystems) and quantitated using Applied Biosystems StepOnePlus Real-
Time PCR Systems (Applied Biosystems). Duplicate runs of each sample
were normalized to 16S rRNA (liver) or cyclophilin (hepatocytes) to determine
relative expression levels. The sequences for the primer pairs used in this
study are listed in Table S1.
Glucose Production Assay
Glucose production assay was performed following Yoon et al. (2001) with
modifications. Briefly, primary hepatocytes were cultured in DMEM (5 mM
glucose) containing 100 nM dexamethasone in the presence or absence of
50 nM insulin for 16 hr. Cells were washed three times with glucose-free
DMEM without phenol red and then incubated with glucose production solu-
tion containing 2 mM sodium pyruvate, 20 mM lactate, 100 nM dexametha-
sone, and 1 mM 8-bromo-cAMP with or without 100 nM insulin. After 12 hr
of incubation, glucose concentration in the media was measured using
a glucose oxidase kit (Sigma), normalized to the protein amount of the cells.
The assay was done in triplicate and values were expressed as arbitrary units
relative to control hepatocytes without insulin.
Measurement of Glucose Uptake
Glucose uptake by primary hepatocytes was analyzed following Yang et al.
(2002) with modifications. Briefly, after 12 hr serum starvation, cells were
cultured in DMEM containing 25 mM glucose, 100 nM dexamethasone, and
10 nM (in the Akt2 restoration experiment) or 50 nM (in the GK restoration
experiment) insulin for 12 hr. To measure the rate of glucose uptake, cells
were washed three times with PBS and then incubated for 3 hr in DMEM con-
taining 1 mCi/ml 2-Deoxy-2[1,2-3H]glucose (PerkinElmer Life Sciences). The
cells were washed three times with ice-cold PBS and solubilized in 1% SDS.
The radioactivity of an aliquot was determined in a scintillation counter. Each
assay was done in triplicate, and results were expressed as cpm in the cell
lysate/mg of protein.
De Novo Lipid Synthesis Measurement
For de novo lipogenesis analysis, primary hepatocytes were precultured in the
same way as for the glucose uptake experiment. Then cells were incubated in
culture medium containing 0.5 mM sodium acetate and 0.8 mCi/ml [1-14C] ace-
tic acid (Amersham) for 2 hr. After washing with PBS, the cells were lyzed in
0.5 M KOH. The lysates were neutralized with 6% Na2SO4, then the lipids
were extracted using sequential extraction with chloroform:methanol (2:1)
and chloroform:methanol:H2O (10:10:3). Radioactivity in lipid-containing
phase was measured using scintillation counter. Each assay was done in trip-
licate, and results were expressed as cpm in the original cell lysate/mg of
protein.
Statistical analysis
Student’s unpaired t test was used to determine differences among two
groups. Significance was judged when p value is less than 0.05. Error bars
in figures represent standard error of the mean (SEM).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2012.03.015.
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